Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.

Adakitug is a monoclonal antibody commercialized by Bristol-Myers Squibb, with a leading Phase II program in Solid Tumor.

(Michelle Mullins/for the Daily Southtown) Addy was diagnosed with metastatic hepatocellular carcinoma in July 2021. That ...

Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital, is the corresponding author of a paper published in ...